ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

The Impact of De Novo Post-Transplant Diabetes on Hepatic Steatosis and Liver Transplant Outcomes.

C. Reuter,1 R.-A. Lee,1 R. Watkins,3 S. Lieber,2 K. Szempruch,1 D. Gerber,4 G. DeCherney,2 A. Barritt IV.2

1Department of Pharmacy, UNC Health Care, Chapel Hill, NC
2Department of Medicine, UNC Health Care, Chapel Hill, NC
3UNC Center for Transplant Care, UNC Health Care, Chapel Hill, NC
4Department of Surgery, UNC Health Care, Chapel Hill, NC

Meeting: 2017 American Transplant Congress

Abstract number: D194

Keywords: Hyperglycemia, Liver transplantation, Outcome, Post-transplant diabetes

Session Information

Session Name: Poster Session D: Liver - Kidney Issues in Liver Transplantation

Session Type: Poster Session

Date: Tuesday, May 2, 2017

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall D1

Introduction: As the prevalence of diabetes (DM) increases in the general population, it is also increasing in the transplant (Tx) population. Post-transplant diabetes (PTDM) has historically led to inferior outcomes after Tx. With the rising population of Tx for fatty liver disease, the impact of DM, de novo PTDM, and, hepatic steatosis on post-liver Tx outcomes has not been clearly defined.

Purpose: To determine the incidence and prevalence of PTDM, post-Tx hepatic steatosis and the impact on liver Tx outcomes.

Methods: This was a single center retrospective cohort study from 2003 to 2016 of adult patients undergoing liver Tx. Pediatric, acute liver failure and retransplants were excluded. DM was defined as ≥ 2 random glucose levels ≥ 200 mg/dl at 1 year. Glucose levels in the first 30 days post-Tx were excluded. The outcomes were recurrent or de novo DM, steatosis at 1, 3, 5 years, and patient survival. Time-to-event analyses were performed with Kaplan-Meier survival curves.

Results: 433 patients met inclusion criteria. 13% of Tx were performed for NAFLD, and 23% of patients had DM at the time of Tx. 81% of patients with DM at the time of Tx continued to have uncontrolled DM at 1 year. Among patients without DM at Tx, 44% developed de novo PTDM by 5 years; 77% of these occurred in the first 12 months (Figure 1). PTDM was associated with de novo hepatic steatosis at 1,3 and 5 years (6% vs 4%, 17% vs 9%, and 27% vs 17%, p=0.05). There was a numerical trend toward inferior survival of patients with DM at 5 years (78% vs 72%) in unadjusted analysis.

Conclusion: De novo PTDM is common and the majority occurs within the first year. PTDM is associated with post-Tx hepatic steatosis and a trend toward inferior patient survival. The early onset of PTDM provides a potential window for intervention that may reduce the risk of steatosis and decreased survival.

CITATION INFORMATION: Reuter C, Lee R.-A, Watkins R, Lieber S, Szempruch K, Gerber D, DeCherney G, Barritt IV A. The Impact of De Novo Post-Transplant Diabetes on Hepatic Steatosis and Liver Transplant Outcomes. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Reuter C, Lee R-A, Watkins R, Lieber S, Szempruch K, Gerber D, DeCherney G, IV ABarritt. The Impact of De Novo Post-Transplant Diabetes on Hepatic Steatosis and Liver Transplant Outcomes. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/the-impact-of-de-novo-post-transplant-diabetes-on-hepatic-steatosis-and-liver-transplant-outcomes/. Accessed May 8, 2025.

« Back to 2017 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences